Becton Dickinson gains FDA OK for two-pronged smallpox vaccine needle:
This article was originally published in Clinica
Executive Summary
Becton Dickinson has gained US FDA 510(k) clearance for its bifurcated, two-pronged needle for the delivery of the smallpox vaccine. The needle is designed to aid in the preparation for mass immunisation against the disease, in the event of a bioterrorist threat, said the Franklin Lakes, New Jersey firm. The company is also developing a "safety-engineered" version of the product to help prevent needlestick injuries.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.